Gilead Sciences is paying up to $7.8 billion for cancer drug developer Arcellx, a move that underscores the intense competition among pharmaceutical giants to acquire smaller biotech firms with proven pipelines. This acquisition highlights Gilead's strategic push to bolster its oncology portfolio amid a crowded market.

The deal values Arcellx at a substantial premium, reflecting investor confidence in its cancer therapies. Arcellx is expected to accelerate Gilead's entry into targeted cancer treatments, potentially giving it a competitive edge against rivals like Roche and Pfizer. Up to $7.8 billion represents one of the largest biotech deals in recent memory, signaling that cash-rich pharma companies are willing to pay premium prices for innovation. The transaction comes as major players scramble to secure assets that can deliver blockbuster drugs, driving up valuations across the sector.